glp 1 drugs and gastroparesis Drug-Induced Product Liability Clinical Consequences of Delayed Gastric
Description
10.1111/dom.12595 [DOI] [PubMed] [Google Scholar] 50.Almagthali AG, Alkhaldi EH, Alzahrani AS, Alghamdi AK, Alghamdi WY, Kabel AM
[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al
Treatment starts with a lower dose of tirzepatide, gradually increasing to reach weight loss and health goals
Their efficacy potential to lower HbA1c is in the range between 0.5 and 1.0% and their safety profile is favorable
Regular physical activity can also contribute to a healthy lifestyle
Mounjaro generally outperforms Ozempic in terms of A1C reduction and weight loss
